Renal

Localized

T1b or greater (has not spread beyond the kidney)

IRB#16576
Atezolizumab vs placebo as adjuvant therapy following nephrectomy

IRB#16300
Merck 3475

No Prior Systemic Therapy

Matasectomy Candidate

IRB#9241
Pazopanib vs. Placebo in Patients with mRCC

No trials Currently Available

Cytoreductive Nephrectomy Candidate

IRB#11283
A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone (Including a Lead-In Phase IB Dose-Escalation Portion) In Patients With Advanced Or Metastatic Renal Cell Carcinoma.

IRB#16085
S1500 – Cabozantinib, Crizotinib, Savolitinib and sunitinib

Clear Cell

Non- Clear Cell

Metastatic/advanced

No Trials Currently Available

Prior Systemic Therapy

Key

- Open for Enrollment
- In Development
- Enrollment on Hold